Nanobiotix reports voting rights and share capital data
Nanobiotix disclosed its voting rights and share capital data as of May 31, 2026, reporting 50,807,903 shares outstanding. Total theoretical voting rights stood at 54,304,858, while exercisable voting rights were 54,282,740.
*this image is generated using AI for illustrative purposes only.
Nanobiotix has released its voting rights and share capital data as of May 31, 2026. The company reported 50,807,903 shares outstanding, with total theoretical voting rights standing at 54,304,858 and total exercisable voting rights at 54,282,740.
The total number of theoretical voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
The total number of exercisable voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the company. This figure is released to ensure that the public is properly informed.
Share Capital and Voting Rights Summary
| Date | Number of Shares Outstanding | Total voting rights, theoretical | Total voting rights, exercisable |
|---|---|---|---|
| May 31, 2026 | 50,807,903 | 54,304,858 | 54,282,740 |
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France. The company is listed on Euronext Paris and the Nasdaq Global Select Market.
How might the current share capital structure influence potential strategic partnerships or acquisitions?
What impact could recent changes in voting rights have on shareholder governance decisions?
How might Nanobiotix's clinical trial progress affect its share capital and voting rights in the future?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
